Evotec (EVO) vs Neurogene (NGNE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neurogene (NGNE) has outperformed Evotec (EVO) over the past year, gaining 2.6% versus a loss of 60.6%. Over five years, NGNE leads with a -81.6% price change compared with -93.1% for EVO. Evotec is the larger company by market cap ($543.7 million vs $540.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVO | NGNE |
|---|---|---|
| Share price | $1.53 | $27.01 |
| Market cap | $543.75M | $540.41M |
| 1-day change | -2.55% | +1.91% |
| YTD return | -49.03% | +28.64% |
| 1-year return | -60.55% | +2.59% |
| 5-year return | -93.05% | -81.65% |
| EPS (TTM) | $-0.64 | $-5.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.27 | $43.66 |
| 52-week low | $1.50 | $15.93 |
| Distance from 52-week high | -64.17% | -38.15% |
| Analyst consensus | none | none |
| Avg. price target upside | +171.90% | +188.39% |
| Average volume | 105.22K | 247.13K |
| Shares outstanding | 355.39M | 20.01M |
| Employees | 4,461 | 131 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NGNE has outperformed EVO by 63.1 percentage points over the past year.
About Evotec
EVO stock →Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics.
Health Care · Biotechnology: Pharmaceutical Preparations · 4,461 employees
About Neurogene
NGNE stock →Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees
EVO vs NGNE FAQ
Which is bigger, Evotec or Neurogene?
Evotec (EVO) is larger, with a market capitalization of $543.75M compared with $540.41M for Neurogene (NGNE).
Which stock has performed better over the past year, EVO or NGNE?
NGNE returned +2.59% over the past 12 months, compared with -60.55% for EVO (price return, excluding dividends). Past performance does not predict future results.
Are Evotec and Neurogene in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.